symbol,statement_type,period_end,line_item,value
AJANTPHARM.NS,income,2025-03-31 00:00:00,Tax Effect Of Unusual Items,0.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Tax Rate For Calcs,0.226017
AJANTPHARM.NS,income,2025-03-31 00:00:00,Normalized EBITDA,13540000000.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Total Unusual Items,
AJANTPHARM.NS,income,2025-03-31 00:00:00,Total Unusual Items Excluding Goodwill,
AJANTPHARM.NS,income,2025-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,9203900000.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Reconciled Depreciation,1441100000.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Reconciled Cost Of Revenue,10707600000.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,EBITDA,13540000000.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,EBIT,12098900000.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Net Interest Income,-207300000.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Interest Expense,207300000.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Interest Income,
AJANTPHARM.NS,income,2025-03-31 00:00:00,Normalized Income,9203900000.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,9203900000.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Total Expenses,23045600000.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Rent Expense Supplemental,
AJANTPHARM.NS,income,2025-03-31 00:00:00,Diluted Average Shares,125172039.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Basic Average Shares,125120990.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Diluted EPS,73.53
AJANTPHARM.NS,income,2025-03-31 00:00:00,Basic EPS,73.56
AJANTPHARM.NS,income,2025-03-31 00:00:00,Diluted NI Availto Com Stockholders,9203900000.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Average Dilution Earnings,
AJANTPHARM.NS,income,2025-03-31 00:00:00,Net Income Common Stockholders,9203900000.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Net Income,9203900000.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Net Income Including Noncontrolling Interests,9203900000.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Net Income Continuous Operations,9203900000.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Tax Provision,2687700000.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Pretax Income,11891600000.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Other Non Operating Income Expenses,-11530400000.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Special Income Charges,
AJANTPHARM.NS,income,2025-03-31 00:00:00,Other Special Charges,
AJANTPHARM.NS,income,2025-03-31 00:00:00,Write Off,
AJANTPHARM.NS,income,2025-03-31 00:00:00,Impairment Of Capital Assets,
AJANTPHARM.NS,income,2025-03-31 00:00:00,Net Non Operating Interest Income Expense,-207300000.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Interest Expense Non Operating,207300000.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Interest Income Non Operating,
AJANTPHARM.NS,income,2025-03-31 00:00:00,Operating Income,23435400000.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Operating Expense,12338000000.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Other Operating Expenses,
AJANTPHARM.NS,income,2025-03-31 00:00:00,Depreciation And Amortization In Income Statement,1441100000.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Amortization,
AJANTPHARM.NS,income,2025-03-31 00:00:00,Depreciation Income Statement,1441100000.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Selling General And Administration,
AJANTPHARM.NS,income,2025-03-31 00:00:00,Selling And Marketing Expense,
AJANTPHARM.NS,income,2025-03-31 00:00:00,General And Administrative Expense,
AJANTPHARM.NS,income,2025-03-31 00:00:00,Rent And Landing Fees,
AJANTPHARM.NS,income,2025-03-31 00:00:00,Gross Profit,35773400000.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Cost Of Revenue,10707600000.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Total Revenue,46481000000.0
AJANTPHARM.NS,income,2025-03-31 00:00:00,Operating Revenue,46481000000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Tax Effect Of Unusual Items,0.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Tax Rate For Calcs,0.267306
AJANTPHARM.NS,income,2024-03-31 00:00:00,Normalized EBITDA,12565400000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Total Unusual Items,283200000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Total Unusual Items Excluding Goodwill,283200000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,8161700000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Reconciled Depreciation,1354000000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Reconciled Cost Of Revenue,10665700000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,EBITDA,12565400000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,EBIT,11211400000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Net Interest Income,-72100000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Interest Expense,72100000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Interest Income,277100000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Normalized Income,8161700000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,8161700000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Total Expenses,21023100000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Rent Expense Supplemental,73800000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Diluted Average Shares,126010499.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Basic Average Shares,125913298.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Diluted EPS,64.77
AJANTPHARM.NS,income,2024-03-31 00:00:00,Basic EPS,64.82
AJANTPHARM.NS,income,2024-03-31 00:00:00,Diluted NI Availto Com Stockholders,8161700000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Average Dilution Earnings,0.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Net Income Common Stockholders,8161700000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Net Income,8161700000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Net Income Including Noncontrolling Interests,8161700000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Net Income Continuous Operations,8161700000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Tax Provision,2977600000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Pretax Income,11139300000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Other Non Operating Income Expenses,-10239500000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Special Income Charges,34900000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Other Special Charges,-34900000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Write Off,
AJANTPHARM.NS,income,2024-03-31 00:00:00,Impairment Of Capital Assets,
AJANTPHARM.NS,income,2024-03-31 00:00:00,Net Non Operating Interest Income Expense,-72100000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Interest Expense Non Operating,72100000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Interest Income Non Operating,277100000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Operating Income,21064000000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Operating Expense,10357400000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Other Operating Expenses,6214800000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Depreciation And Amortization In Income Statement,1354000000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Amortization,50100000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Depreciation Income Statement,1354000000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Selling General And Administration,3826600000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Selling And Marketing Expense,2531200000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,General And Administrative Expense,1295400000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Rent And Landing Fees,73800000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Gross Profit,31421400000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Cost Of Revenue,10665700000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Total Revenue,42087100000.0
AJANTPHARM.NS,income,2024-03-31 00:00:00,Operating Revenue,42087100000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Tax Effect Of Unusual Items,-19728500.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Tax Rate For Calcs,0.211
AJANTPHARM.NS,income,2023-03-31 00:00:00,Normalized EBITDA,8912400000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Total Unusual Items,-93500000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Total Unusual Items Excluding Goodwill,-93500000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,5879800000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Reconciled Depreciation,1308000000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Reconciled Cost Of Revenue,11167300000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,EBITDA,8818900000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,EBIT,7510900000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Net Interest Income,26200000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Interest Expense,58400000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Interest Income,84600000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Normalized Income,5953571500.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,5879800000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Total Expenses,30277600000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Rent Expense Supplemental,75900000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Diluted Average Shares,128122871.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Basic Average Shares,128118877.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Diluted EPS,45.89
AJANTPHARM.NS,income,2023-03-31 00:00:00,Basic EPS,45.89
AJANTPHARM.NS,income,2023-03-31 00:00:00,Diluted NI Availto Com Stockholders,5879800000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Average Dilution Earnings,0.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Net Income Common Stockholders,5879800000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Net Income,5879800000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Net Income Including Noncontrolling Interests,5879800000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Net Income Continuous Operations,5879800000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Tax Provision,1572700000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Pretax Income,7452500000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Other Non Operating Income Expenses,61500000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Special Income Charges,-53500000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Other Special Charges,53500000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Write Off,-8400000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Impairment Of Capital Assets,200000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Net Non Operating Interest Income Expense,26200000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Interest Expense Non Operating,58400000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Interest Income Non Operating,84600000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Operating Income,6797600000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Operating Expense,19110300000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Other Operating Expenses,6729000000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Depreciation And Amortization In Income Statement,1308000000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Amortization,41000000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Depreciation Income Statement,1267000000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Selling General And Administration,3426800000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Selling And Marketing Expense,2267100000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,General And Administrative Expense,1159700000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Rent And Landing Fees,75900000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Gross Profit,25907900000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Cost Of Revenue,11167300000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Total Revenue,37075200000.0
AJANTPHARM.NS,income,2023-03-31 00:00:00,Operating Revenue,37075200000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Tax Effect Of Unusual Items,46569280.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Tax Rate For Calcs,0.2164
AJANTPHARM.NS,income,2022-03-31 00:00:00,Normalized EBITDA,10234600000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Total Unusual Items,215200000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Total Unusual Items Excluding Goodwill,215200000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,7126800000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Reconciled Depreciation,1253000000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Reconciled Cost Of Revenue,8867200000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,EBITDA,10449800000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,EBIT,9196800000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Net Interest Income,44500000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Interest Expense,102000000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Interest Income,146500000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Normalized Income,6958169280.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,7126800000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Total Expenses,24722500000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Rent Expense Supplemental,65400000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Diluted Average Shares,129662555.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Basic Average Shares,129658060.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Diluted EPS,54.96
AJANTPHARM.NS,income,2022-03-31 00:00:00,Basic EPS,54.97
AJANTPHARM.NS,income,2022-03-31 00:00:00,Diluted NI Availto Com Stockholders,7126800000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Average Dilution Earnings,
AJANTPHARM.NS,income,2022-03-31 00:00:00,Net Income Common Stockholders,7126800000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Net Income,7126800000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Net Income Including Noncontrolling Interests,7126800000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Net Income Continuous Operations,7126800000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Tax Provision,1968000000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Pretax Income,9094800000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Other Non Operating Income Expenses,152900000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Special Income Charges,-78500000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Other Special Charges,38700000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Write Off,0.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Impairment Of Capital Assets,39800000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Net Non Operating Interest Income Expense,44500000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Interest Expense Non Operating,102000000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Interest Income Non Operating,146500000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Operating Income,8118800000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Operating Expense,15855300000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Other Operating Expenses,5401800000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Depreciation And Amortization In Income Statement,1252900000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Amortization,39400000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Depreciation Income Statement,1213500000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Selling General And Administration,3137200000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Selling And Marketing Expense,2185700000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,General And Administrative Expense,951500000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Rent And Landing Fees,65400000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Gross Profit,23974100000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Cost Of Revenue,8867200000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Total Revenue,32841300000.0
AJANTPHARM.NS,income,2022-03-31 00:00:00,Operating Revenue,32841300000.0
AJANTPHARM.NS,income,2021-03-31 00:00:00,Tax Effect Of Unusual Items,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Tax Rate For Calcs,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Normalized EBITDA,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Total Unusual Items,25900000.0
AJANTPHARM.NS,income,2021-03-31 00:00:00,Total Unusual Items Excluding Goodwill,25900000.0
AJANTPHARM.NS,income,2021-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Reconciled Depreciation,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Reconciled Cost Of Revenue,
AJANTPHARM.NS,income,2021-03-31 00:00:00,EBITDA,
AJANTPHARM.NS,income,2021-03-31 00:00:00,EBIT,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Net Interest Income,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Interest Expense,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Interest Income,35100000.0
AJANTPHARM.NS,income,2021-03-31 00:00:00,Normalized Income,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Total Expenses,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Rent Expense Supplemental,24300000.0
AJANTPHARM.NS,income,2021-03-31 00:00:00,Diluted Average Shares,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Basic Average Shares,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Diluted EPS,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Basic EPS,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Diluted NI Availto Com Stockholders,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Average Dilution Earnings,0.0
AJANTPHARM.NS,income,2021-03-31 00:00:00,Net Income Common Stockholders,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Otherunder Preferred Stock Dividend,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Net Income,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Net Income Including Noncontrolling Interests,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Net Income Continuous Operations,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Tax Provision,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Pretax Income,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Other Non Operating Income Expenses,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Special Income Charges,-97700000.0
AJANTPHARM.NS,income,2021-03-31 00:00:00,Other Special Charges,22100000.0
AJANTPHARM.NS,income,2021-03-31 00:00:00,Write Off,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Impairment Of Capital Assets,75600000.0
AJANTPHARM.NS,income,2021-03-31 00:00:00,Net Non Operating Interest Income Expense,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Interest Expense Non Operating,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Interest Income Non Operating,35100000.0
AJANTPHARM.NS,income,2021-03-31 00:00:00,Operating Income,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Operating Expense,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Other Operating Expenses,3646200000.0
AJANTPHARM.NS,income,2021-03-31 00:00:00,Depreciation And Amortization In Income Statement,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Amortization,46900000.0
AJANTPHARM.NS,income,2021-03-31 00:00:00,Depreciation Income Statement,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Selling General And Administration,2768100000.0
AJANTPHARM.NS,income,2021-03-31 00:00:00,Selling And Marketing Expense,2384100000.0
AJANTPHARM.NS,income,2021-03-31 00:00:00,General And Administrative Expense,384000000.0
AJANTPHARM.NS,income,2021-03-31 00:00:00,Rent And Landing Fees,24300000.0
AJANTPHARM.NS,income,2021-03-31 00:00:00,Gross Profit,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Cost Of Revenue,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Total Revenue,
AJANTPHARM.NS,income,2021-03-31 00:00:00,Operating Revenue,
